Literature DB >> 29871962

Severe bone marrow suppression due to methotrexate toxicity following aceclofenac-induced acute kidney injury.

Robin George Manappallil1, Durga Prasan2, Jayameena Peringat3, Illolil Kuniyil Biju4.   

Abstract

Methotrexate is one of the most commonly used drugs in autoimmune disorders like rheumatoid arthritis. Gastrointestinal symptoms like nausea and stomatitis, skin rashes, alopecia, central nervous system symptoms like headache and confusion, hepatotoxicity and myelosuppression are some of the adverse effects. However, low oral doses on a weekly basis seldom show any signs of toxicity. Leucovorin or folinic acid is given along with methotrexate as rescue to reduce the toxic effects like bone marrow suppression. Non-steroidal anti-inflammatory drugs, like aceclofenac, are also used in chronic inflammatory conditions like rheumatoid arthritis and osteoarthritis. Nephrotoxicity is one of the adverse effects of both methotrexate and non-steroidal anti-inflammatory drugs; and its combined administration should be done with caution. This is a case of an elderly woman, a known case of rheumatoid arthritis, who presented in severe bone marrow suppression due to methotrexate toxicity following aceclofenac-induced acute kidney injury. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  acute renal failure; rheumatoid arthritis

Mesh:

Substances:

Year:  2018        PMID: 29871962      PMCID: PMC5990089          DOI: 10.1136/bcr-2018-224722

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

1.  Adverse effects of low dose methotrexate in rheumatoid arthritis patients.

Authors:  Syed Tanveer Abbas Gilani; Dilshad Ahmed Khan; Farooq Ahmad Khan; Mushtaq Ahmed
Journal:  J Coll Physicians Surg Pak       Date:  2012-02       Impact factor: 0.711

2.  Disposition kinetics of sulphadiazine in normal and diabetic rabbits.

Authors:  T Iqbal; R Nawaz; A Ilahi; M Nawaz
Journal:  J Pak Med Assoc       Date:  1989-02       Impact factor: 0.781

3.  Methotrexate in rheumatoid arthritis. Health and Public Policy Committee, American College of Physicians.

Authors: 
Journal:  Ann Intern Med       Date:  1987-09       Impact factor: 25.391

4.  Severe pancytopenia associated with low-dose methotrexate therapy for rheumatoid arthritis.

Authors:  J M Calvo-Romero
Journal:  Ann Pharmacother       Date:  2001-12       Impact factor: 3.154

Review 5.  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.

Authors:  Z Ortiz; B Shea; M Suarez Almazor; D Moher; G Wells; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2000

6.  [Pancytopenia in rheumatoid arthritis treated with methotrexate].

Authors:  F Laroche; S Perrot; C J Menkès
Journal:  Presse Med       Date:  1996-09-07       Impact factor: 1.228

7.  High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model.

Authors:  E Smeland; O M Fuskevåg; K Nymann; J S Svendesn; R Olsen; S Lindal; R M Bremnes; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

8.  Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal.

Authors:  B Mayall; G Poggi; J D Parkin
Journal:  Med J Aust       Date:  1991-10-07       Impact factor: 7.738

9.  Methotrexate toxicity induced by acute renal failure.

Authors:  A Strang; T Pullar
Journal:  J R Soc Med       Date:  2004-11       Impact factor: 18.000

10.  Macrophage Activation Syndrome as Onset of Systemic Lupus Erythematosus: A Case Report and a Review of the Literature.

Authors:  Guido Granata; Dario Didona; Giuseppina Stifano; Aldo Feola; Massimo Granata
Journal:  Case Rep Med       Date:  2015-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.